Skip to main content

Journal of Gastrointestinal Cancer

Ausgabe 1/2022

Inhalt (35 Artikel)

Original Research

Port-Site Metastases in Incidentally Detected Carcinoma Gall Bladder: Role of 18F-FDG PET/CT and Patient Outcome

Vivek Kumar Saini, AftabNazar Hassan, Ashish Kumar Singh, Manish Ora, Sanjay Gambhir

Original Research

Histopathological, Radiological, and Demographic Factors Predicting the Response to Neoadjuvant Therapy for Rectal Cancer

Emine Yildirim, Sibel Bektas, Zekeriya Pelen, Irem Yanik, Ahmet Muzaffer Er, Ferhat Cengel, Perihan Özkan Gumuskaya

Original Research

Prognostic Factors for Survival in Transverse Colon Cancers

Ahmet Küçükarda, Ali Gökyer, Sezin Sayın, İvo Gökmen, Erkan Özcan, Osman Köstek, Muhammet Bekir Hacıoğlu, Sernaz Uzunoğlu, İrfan Çiçin, Bülent Erdoğan

Original Research

Metastatic Pancreatic Cancer Second-Line Treatment Options: Is the Difference Only in Cost?

Serkan Yıldırım, A. P. Erdoğan, M. Karateke, C. Yılmaz, A. Özveren, G. Bulut, F. Ekinci, E. Almuradova

Original Research

Could the Inflammatory Prognostic Index Predict the Efficacy of Regorafenib in Patients with Metastatic Colorectal Cancer?

Atike Pınar Erdoğan, Ferhat Ekinci, Aykut Karabaş, Onur Yazdan Balçık, Sabri Barutça, Ahmet Dirican

Original Research

Palliative Biliary Drainage Has No Effect on Survival in Pancreatic Cancer: Medical Oncology Perspective

Atike Pınar Erdoğan, Ferhat Ekinci, Serkan Yıldırım, Ahmet Özveren, Gamze Göksel

Original Research

The View of Turkish Oncologists Regarding MSI Status and Tumor Localization in Stage II and III Colon Cancer

Ismail Beypinar, Hacer Demir, Murat Araz, Meltem Baykara, Nuri Faruk Aykan

Original Research

Factors affecting the survival of patients with colorectal cancer using random survival forest

Ghodratollah Roshanaei, Malihe Safari, Javad Faradmal, Mohammad Abbasi, Salman Khazaei

Original Research

Overexpression of HOXA-AS2 LncRNA in Patients with Gastric Cancer and Its Association with Helicobacter pylori Infection

Ali Rajabi, Atousa Riahi, Hanie Shirabadi-Arani, Yaghoub Moaddab, Mehdi Haghi, Reza Safaralizadeh

Original Research

Association of Epidermal Growth Factor 61A>G, Survivin -31G>C, and EFNA1 -1732G>A Polymorphisms with Susceptibility to Colorectal Cancer

Fatemeh Asadian, Mohammadamin Ghadyani, Mohamad Hossein Antikchi, Seyed Alireza Dastgheib, Hossein Neamatzadeh, Elnaz Sheikhpour, Sahel Khajehnoori, Seyed Sajjad Tabei

Original Research

Risk Score Model for Liver Transplant Outcomes after Preoperative Locoregional Therapy for Hepatocellular Carcinoma

Abu Bakar Hafeez Bhatti, Muhammad Hassan, Atif Rana, Nusrat Yar Khan, Zahid Amin Khan, Haseeb Haider Zia

Original Research

Operative and Oncological Outcomes After D2 Versus D1 Gastrectomy of Operable Gastric Cancer: an Observational Study

Mohamed M. Elmessiry, Tarek A. El-Fayoumi, Haytham M. Fayed, Ahmed A. Gebaly, Eman A. E. Mohamed

Original Research

Cytotoxic and Apoptotic Effects of Celecoxib and Topotecan on AGS and HEK 293 Cell Lines

Kimia Badalanloo, Tahereh Naji, Rahim Ahmadi

Original Research

Patterns of Care and Outcomes of Low-Lying Adenocarcinoma and Squamous Cell Carcinoma of the Rectum

Nikita Malakhov, Joseph K. Kim, Paul Adedoyin, Ashley Albert, David Schreiber, Anna Lee

Original Research

Prognostic Factors of Rectal Cancer in Southern Iran

Seyed Vahid Hosseini, Abbas Rezaianzadeh, Salar Rahimikazerooni, Alimohammad Bananzadeh, Afrouz Farghadin, Mohammad Zare Band Amiry, Ahmad Izadpanah, Mohammad Mohammadianpanah, Sohrab Iranpour

Original Research

Incremental value of endoscopic brush cytology in response assessment after chemo-irradiation for Esophageal cancer

Shreyasee Karmakar, Naveen Mummudi, Sarbani Ghosh-Laskar, Anil Tibdewal, Rajiv Kumar, Prachi Patil, Shaesta Mehta, Vanita Noronha, Kumar Prabhash, Nilendu Purandare, Saleem Pathuthara, Jai Prakash Agarwal

Original Research

Incidence, Survival and Prognostic Factors of Oesophagogastric Cancer

Nurul Syuhada Ishak, Hanif Abdul Rahman, Shirley H. F. Lee, Shir Kiong Lu, Lin Naing

Original Research

Disaggregating Data on Pacific Islander Gastric Cancer Patients Reveals Survival Disparity

Gene T. Yoshikawa, Nicholas Simon, Ryon K. Nakasone, Jared D. Acoba

Original Research

Outcomes of Squamous Cell Carcinoma Anal Canal treated with IMRT-VMAT–based Concurrent Chemoradiation: a Single Institutional Experience

Kaalindi Singh, Arvind Sathyamurthy, Jeba Karunya Ramireddy, Thomas Samuel Ram

Original Research

Decreased expression of TRIM3 gene predicts a poor prognosis in gastric cancer

Javad Farhadi, Ladan Goshayeshi, Alireza Motavalizadehkakhky, Jamshid Mehrzad, Hassan Mehrad-Majd

Original Research

Safety and tolerability of regorafenib: a real-life experience

Youssif Abo Elseud, Amrou Shaaban, Asit Mohanty, Jasem Albarrak

Original Research

Immunohistochemical Expression Pattern of MLH1, MSH2, MSH6, and PMS2 in Tumor Specimen of Iranian Gastric Carcinoma Patients

Sina Salari, Mojtaba Ghadyani, Mahdi Karimi, Masoud Mortezazadeh, Farzan Vahedifard

Original Research

Endoscopic Ultrasonography is a Promising Tool for Preoperative Prediction of the Operability of Pancreatic Carcinoma

Tarek Ezzat Abdellatif, Khaled Safwat, Hazem Hakim Elmenshawy, Wael Abdalla, Sameh Mohamed Naguib

Original Research

Gastric Cancer Incidence and Mortality in French Guiana: South American or French?

Laure Manuella Imounga, Juliette Plenet, Sophie Belliardo, Elie Chow Chine, Dominique Louvel, Beatrice Cenciu, Pierre Couppié, Kinan Drak Alsibai, Mathieu Nacher

Original Research

Onion Extract Encapsulated on Nano Chitosan: a Promising Anticancer Agent

Abdulrahman Ali Alzandi, Deyala M. Naguib, Al-Shimaa M. Abas

Author Correction

Correction to: Onion Extract Encapsulated on Nano Chitosan: A Promising Anticancer Agent

Abdulrahman Ali Alzandi, Deyala M. Naguib, Al-Shimaa M. Abas

Case Report

A Case Study on Modeling the Time to Recurrence of Gastric Cancer Patients

Mesfin Esayas Lelisho, Adem Aregaw Seid, Digvijay Pandey

Author Correction

Author Correction: A Case Study on Modeling the Time to Recurrence of Gastric Cancer Patients

Mesfin Esayas Lelisho, Adem Aragaw Seid, Digvijay Pandey

Original Research

Investigating Trends of Incidence Rates of Esophageal Cancer Divided by Squamous Cell Carcinoma and Adenocarcinoma in Southern Iran: a 10-Year Experience

Mahnaz Hosseini-Bensenjan, Hossein Molavi Vardanjani, Sezaneh Haghpanah, Zahra Khosravizadegan, Kamran Bagheri-Lankarani

Correction

Correction to: Investigating Trends of Incidence Rates of Esophageal Cancer Divided by Squamous Cell Carcinoma and Adenocarcinoma in Southern Iran: a 10-Year Experience

Mahnaz Hosseini-Bensenjan, Hossein Molavi Vardanjani, Sezaneh Haghpanah, Zahra Khosravizadegan, Kamran Bagheri-Lankarani

Original Research

RETRACTED ARTICLE: Upregulation of miR-21 Expression in Gastric Cancer and Its Clinicopathological Feature Association

Fatima Ezzahra Rihane, Driss Erguibi, Maryame Lamsisi, Farid Chehab, Moulay Mustapha Ennaji

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.